Actionable news
All posts from Actionable news
Actionable news in AEZS: AEterna Zentaris Inc.,

Igenica Biotherapeutics Enters Into a Strategic Oncology Research Agreement with MedImmune

BURLINGAME, Calif., Oct 28, 2015 (BUSINESS WIRE) -- Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative antibody-based therapies for the treatment of cancer, announced today that it has entered into an oncology research agreement with MedImmune, the global biologics research and development arm of AstraZeneca AZN, -0.19% Igenica and MedImmune will evaluate the potential of antibody-drug conjugates (ADCs) targeting Surface Antigen in Leukemia (SAIL), a novel cell surface protein with high prevalence of expression in a variety of hematologic malignancies and several solid tumors. Preclinical data have supported the selective targeting of tumors expressing SAIL with ADCs.

Under the agreement, Igenica will contribute its proprietary anti-SAIL antibodies, including IGN786, and its proprietary SNAP ADC drug linker, and MedImmune will provide its proprietary anti-tumor payload. Igenica and MedImmune will then jointly investigate the resulting novel ADC in preclinical studies.

MedImmune will receive an option to an exclusive worldwide...